Published in J Virol on October 08, 2008
Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J Virol (2009) 3.67
Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology (2010) 2.90
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature (2015) 2.87
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol (2011) 1.95
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods (2013) 1.66
Evidence that ecotropic murine leukemia virus contamination in TZM-bl cells does not affect the outcome of neutralizing antibody assays with human immunodeficiency virus type 1. J Virol (2009) 1.61
Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells. PLoS Pathog (2015) 1.50
Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. J Immunol Methods (2011) 1.40
Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother (2009) 1.26
Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines. PLoS One (2011) 1.22
RNA helicase A modulates translation of HIV-1 and infectivity of progeny virions. Nucleic Acids Res (2009) 1.22
The formulated microbicide RC-101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS One (2010) 1.19
A lectin isolated from bananas is a potent inhibitor of HIV replication. J Biol Chem (2010) 1.12
MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. Proc Natl Acad Sci U S A (2010) 1.10
Drug-eluting fibers for HIV-1 inhibition and contraception. PLoS One (2012) 1.08
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther (2011) 1.06
Unintended spread of a biosafety level 2 recombinant retrovirus. Retrovirology (2009) 1.02
Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol (2011) 1.00
Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV. Front Oncol (2013) 0.95
Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol (2013) 0.93
Characterization, mapping, and distribution of the two XMRV parental proviruses. J Virol (2011) 0.93
Potent strategy to inhibit HIV-1 by binding both gp120 and gp41. Antimicrob Agents Chemother (2010) 0.92
Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution. Virology (2011) 0.92
Structural Insights into HIV-1 Vif-APOBEC3F Interaction. J Virol (2015) 0.91
4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms. PLoS One (2010) 0.91
Diversity of envelope genes from an uncloned stock of SIVmac251. AIDS Res Hum Retroviruses (2010) 0.91
A highly conserved residue in the C-terminal helix of HIV-1 matrix is required for envelope incorporation into virus particles. J Virol (2011) 0.89
Aromatic residue mutations reveal direct correlation between HIV-1 nucleocapsid protein's nucleic acid chaperone activity and retroviral replication. Virus Res (2012) 0.86
Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses. J Virol (2013) 0.86
Trans-activation, post-transcriptional maturation, and induction of antibodies to HERV-K (HML-2) envelope transmembrane protein in HIV-1 infection. Retrovirology (2014) 0.86
Electrospun solid dispersions of Maraviroc for rapid intravaginal preexposure prophylaxis of HIV. Antimicrob Agents Chemother (2014) 0.85
A comparative proteomic analysis of the soluble immune factor environment of rectal and oral mucosa. PLoS One (2014) 0.84
A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress. Virology (2013) 0.84
A functional role for ADAM10 in human immunodeficiency virus type-1 replication. Retrovirology (2011) 0.84
Optimized Infectivity of the Cell-Free Single-Cycle Human Immunodeficiency Viruses Type 1 (HIV-1) and Its Restriction by Host Cells. PLoS One (2013) 0.84
Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro. PLoS One (2012) 0.83
Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures. PLoS One (2014) 0.83
Phylogeny-directed search for murine leukemia virus-like retroviruses in vertebrate genomes and in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome and prostate cancer. Adv Virol (2011) 0.83
Identification and functional analysis of a second RBF-2 binding site within the HIV-1 promoter. Virology (2011) 0.83
Endogenous Murine Leukemia Viruses: Relationship to XMRV and Related Sequences Detected in Human DNA Samples. Adv Virol (2011) 0.82
UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application. Antimicrob Agents Chemother (2012) 0.82
Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity. Antimicrob Agents Chemother (2015) 0.82
Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures. Int J Nanomedicine (2014) 0.82
Increased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tail. Front Microbiol (2013) 0.82
XMRV induces cell migration, cytokine expression and tumor angiogenesis: are 22Rv1 cells a suitable prostate cancer model? PLoS One (2012) 0.81
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein J Org Chem (2014) 0.81
Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation. Bioorg Med Chem Lett (2015) 0.81
Curcumin inhibits HIV-1 by promoting Tat protein degradation. Sci Rep (2016) 0.80
Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine. PLoS One (2012) 0.80
Short communication: The dead cell: a potent escort for HIV type 1 transinfection. AIDS Res Hum Retroviruses (2009) 0.80
tat Exon 1 exhibits functional diversity during HIV-1 subtype C primary infection. J Virol (2013) 0.79
Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor. J Neuroimmune Pharmacol (2016) 0.79
Highly potent chimeric inhibitors targeting two steps of HIV cell entry. J Biol Chem (2011) 0.79
CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. J Virol (2016) 0.79
Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures. Retrovirology (2017) 0.79
Susceptibility of human lymphoid tissue cultured ex vivo to xenotropic murine leukemia virus-related virus (XMRV) infection. PLoS One (2012) 0.78
Blocking premature reverse transcription fails to rescue the HIV-1 nucleocapsid-mutant replication defect. Retrovirology (2011) 0.78
Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections. Antimicrob Agents Chemother (2015) 0.78
Detection of a gammaretrovirus, XMRV, in the human population: open questions and implications for xenotransplantation. Retrovirology (2010) 0.78
In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors. AIDS Res Hum Retroviruses (2015) 0.78
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection. J Virol (2011) 0.78
Neuroinflammation-Induced Interactions between Protease-Activated Receptor 1 and Proprotein Convertases in HIV-Associated Neurocognitive Disorder. Mol Cell Biol (2015) 0.77
Generation of multiple replication-competent retroviruses through recombination between PreXMRV-1 and PreXMRV-2. J Virol (2013) 0.77
Of Mice and Men: On the Origin of XMRV. Front Microbiol (2011) 0.77
Cellular HIV-1 inhibition by truncated old world primate APOBEC3A proteins lacking a complete deaminase domain. Virology (2014) 0.76
Frequent infection of human cancer xenografts with murine endogenous retroviruses in vivo. Viruses (2015) 0.76
Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors. Retrovirology (2016) 0.76
Prevalence and characterization of murine leukemia virus contamination in human cell lines. PLoS One (2015) 0.76
Analysis of the N-terminal positively charged residues of the simian immunodeficiency virus Vif reveals a critical amino acid required for the antagonism of rhesus APOBEC3D, G, and H. Virology (2013) 0.76
A Conserved Glycan in the C2 Domain of HIV-1 Envelope Acts as a Molecular Switch to Control X4 Utilization by Clonal Variants with Identical V3 Loops. PLoS One (2015) 0.76
Lentiviral expression system for the purification of secreted proteins from human cell cultures. BMC Biotechnol (2016) 0.75
DYRK1A Controls HIV-1 Replication at a Transcriptional Level in an NFAT Dependent Manner. PLoS One (2015) 0.75
A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support. Retrovirology (2016) 0.75
TLR2 ligation enhances HIV-1 replication in activated CCR6+CD4+ T cells by increasing virus entry and establishing a more permissive environment to infection. J Virol (2016) 0.75
Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies. Antimicrob Agents Chemother (2015) 0.75
Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity. Antimicrob Agents Chemother (2016) 0.75
HIV Vpu Interferes with NF-κB Activity but Not with Interferon Regulatory Factor 3. J Virol (2015) 0.75
The Cellular Thioredoxin-1/Thioredoxin Reductase-1 Driven Oxidoreduction Represents a Chemotherapeutic Target for HIV-1 Entry Inhibition. PLoS One (2016) 0.75
Membrane-Active Sequences within gp41 Membrane Proximal External Region (MPER) Modulate MPER-Containing Peptidyl Fusion Inhibitor Activity and the Biosynthesis of HIV-1 Structural Proteins. PLoS One (2015) 0.75
Prevention of contamination by xenotropic murine leukemia virus-related virus: susceptibility to alcohol-based disinfectants and environmental stability. Appl Environ Microbiol (2014) 0.75
Suppressor of cytokine signaling 1 counteracts rhesus macaque TRIM5α-induced inhibition of human immunodeficiency virus type-1 production. PLoS One (2014) 0.75
Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide. Antimicrob Agents Chemother (2013) 0.75
HIV-1 resistance to dolutegravir is affected by cellular histone acetyltransferase activity. J Virol (2017) 0.75
Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer. Bioorg Med Chem Lett (2017) 0.75
Further Characterization of the Bifunctional HIV Entry Inhibitor sCD4-FIT45. Mol Ther Nucleic Acids (2017) 0.75
Epigenetic metabolite acetate inhibits class I/II histone deacetylases, promotes histone acetylation and increases HIV-1 integration in CD4(+) T cells. J Virol (2017) 0.75
SIVmac239, but not SIVmac316, binds and utilizes human CD4 more efficiently than rhesus CD4. J Virol (2017) 0.75
Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes. Retrovirology (2017) 0.75
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol (1998) 10.94
Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci U S A (1988) 9.35
CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA. Cancer (1965) 8.54
Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus. Proc Natl Acad Sci U S A (1985) 8.53
A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell (1989) 7.64
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Factors involved in production of helper virus-free retrovirus vectors. Somat Cell Mol Genet (1986) 6.48
The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol (1984) 5.80
Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int J Cancer (1977) 4.53
Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science (1990) 4.28
Deletion mutants of Moloney murine leukemia virus which lack glycosylated gag protein are replication competent. J Virol (1983) 3.04
Host range and interference studies of three classes of pig endogenous retrovirus. J Virol (1998) 2.94
Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J Virol (1990) 2.66
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Primary structure of the T3 gamma subunit of the T3/T cell antigen receptor complex deduced from cDNA sequences: evolution of the T3 gamma and delta subunits. EMBO J (1986) 2.25
Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement. Proc Natl Acad Sci U S A (1994) 1.84
Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75. Virology (2003) 1.77
Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. Proc Natl Acad Sci U S A (2007) 1.56
Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J Virol (2003) 1.51
Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells. J Virol (1998) 1.22
An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions. Nucleic Acids Res (1993) 1.22
High throughput detection of retrovirus-associated reverse transcriptase using an improved fluorescent product enhanced reverse transcriptase assay and its comparison to conventional detection methods. J Virol Methods (1999) 1.17
Differential expression in human and mouse cells of human immunodeficiency virus pseudotyped by murine retroviruses. J Virol (1990) 1.15
PCR-based cloning and immunocytological titration of infectious porcine endogenous retrovirus subgroup A and B. J Gen Virol (2002) 1.14
Immunological and biochemical characterisation of type C viruses isolated from cultured human AML cells. Nature (1976) 1.14
Analysis of retroviral packaging lines for generation of replication-competent virus. Virology (1990) 1.13
Transmissible retrovirus in Epstein-Barr virus-producer B95-8 cells. Virology (1995) 1.06
Complete replacement of membrane cholesterol with 4,4',14-trimethyl sterols in a human T cell line defective in lanosterol demethylation. J Biol Chem (1992) 1.04
Adaptation of the fluorogenic 5'-nuclease chemistry to a PCR-based reverse transcriptase assay. Biotechniques (1998) 1.04
Characterisation of a virus (HL23V) isolated from cultured acute myelogenous leukaemic cells. Nature (1976) 1.01
Characterization of a C-type retrovirus isolated from an HIV infected cell line: complete nucleotide sequence. Arch Virol (1998) 1.01
Insertion of SMRV-H viral DNA at the c-myc gene locus of a BL cell line and presence in established cell lines. Int J Cancer (1992) 0.96
CD4(+) and CD8(+) T cell death during human immunodeficiency virus infection in vitro. Virology (2001) 0.93
Isolation of a C-type retrovirus from an HIV infected cell line. Arch Virol (1993) 0.92
Selective HIV-1-induced downmodulation of CD4 and coreceptors. Arch Virol (2000) 0.92
Use of a quantitative product-enhanced reverse transcriptase assay to monitor retrovirus levels in mAb cell-culture and downstream processing. Biotechnol Prog (2001) 0.91
Properties of the oncornavirus particles isolated from P3HR-1 and Raji human lymphoblastoid cell lines. Isr J Med Sci (1977) 0.90
One-step fluorescent probe product-enhanced reverse transcriptase assay. Biotechniques (1998) 0.90
Evidence for type-C retrovirus production by Burkitt's lymphoma-derived cell line. Int J Cancer (1980) 0.89
Constitutive production of a murine retrovirus in the human B-lymphoblastoid cell line, DG-75. Virology (1998) 0.87
Identification of human type D retrovirus as a contaminant in a neuroblastoma cell line. Arch Virol (1993) 0.83
Retrovirus type C in the mouse bladder carcinoma cell line MBT-2. J Urol (2000) 0.82
Detection of reverse transcriptase activity in human melanoma cell lines and identification of a murine leukemia virus contaminant. Arch Dermatol Res (2005) 0.82
Budding type C virus particles in a human T cell line derived from acute lymphoblastic leukemia. J Electron Microsc (Tokyo) (1983) 0.79
Transplantation of human rhabdomyosarcoma cells in heterogous hosts: tumors formed and viruses recovered. Bibl Haematol (1975) 0.79
TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature (2011) 6.29
Failure to detect the novel retrovirus XMRV in chronic fatigue syndrome. PLoS One (2010) 4.66
Mouse DNA contamination in human tissue tested for XMRV. Retrovirology (2010) 2.65
Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J Virol (2005) 1.84
Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut (2010) 1.77
Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75. Virology (2003) 1.77
Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol (2003) 1.73
DNA extraction columns contaminated with murine sequences. PLoS One (2011) 1.55
Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proc Natl Acad Sci U S A (2007) 1.51
Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS (2002) 1.33
Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS (2009) 1.28
B-cell depletion reveals a role for antibodies in the control of chronic HIV-1 infection. Nat Commun (2010) 1.26
Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood (2005) 1.24
Function of indoleamine 2,3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol (2006) 1.24
A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. J Virol Methods (2008) 1.21
High prevalence of macrolide resistant Treponema pallidum strains in a London centre. Sex Transm Infect (2011) 1.18
Identification of domains in gag important for prototypic foamy virus egress. J Virol (2005) 1.09
Detection of HIV-1 antiretroviral resistance from patients with persistently low but detectable viraemia. J Virol Methods (2004) 1.09
Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors. PLoS One (2012) 1.08
Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection. Clin Vaccine Immunol (2009) 1.05
Investigation into the presence of and serological response to XMRV in CFS patients. PLoS One (2011) 1.01
Restriction of V3 region sequence divergence in the HIV-1 envelope gene during antiretroviral treatment in a cohort of recent seroconverters. Retrovirology (2013) 1.00
Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. J Gene Med (2005) 0.98
Cell-cycle dependence of foamy virus vectors. J Gen Virol (2004) 0.98
Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog (2011) 0.98
Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. J Virol (2002) 0.97
Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study. Sex Transm Infect (2013) 0.97
Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. J Virol (2002) 0.93
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antivir Ther (2010) 0.92
Chlamydia trachomatis infection increases fallopian tube PROKR2 via TLR2 and NFκB activation resulting in a microenvironment predisposed to ectopic pregnancy. Am J Pathol (2010) 0.91
Comparison of HIV-1 and EIAV-based lentiviral vectors in corneal transduction. Exp Eye Res (2005) 0.90
Effect of vectors on human endothelial cell signal transduction: implications for cardiovascular gene therapy. Arterioscler Thromb Vasc Biol (2005) 0.90
Xenotropic murine leukaemia virus-related virus (XMRV) does not cause chronic fatigue. Trends Microbiol (2011) 0.89
Dendritic cell modification as a route to inhibiting corneal graft rejection by the indirect pathway of allorecognition. Eur J Immunol (2013) 0.88
Getting the measure of syphilis: qPCR to better understand early infection. Sex Transm Infect (2011) 0.84
C. trachomatis Pgp3 antibody prevalence in young women in England, 1993-2010. PLoS One (2013) 0.84
The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α. PLoS One (2012) 0.82
Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. J Virol (2010) 0.82
No Evidence of XMRV or MuLV Sequences in Prostate Cancer, Diffuse Large B-Cell Lymphoma, or the UK Blood Donor Population. Adv Virol (2011) 0.82
Immunolipoplexes: an efficient, nonviral alternative for transfection of human dendritic cells with potential for clinical vaccination. Mol Ther (2005) 0.82
Alterations in cerebrospinal fluid chemokines are associated with maraviroc exposure and in vivo metabolites measurable by magnetic resonance spectroscopy. HIV Clin Trials (2012) 0.80
Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome. J Infect Dis (2002) 0.79
Complete nucleotide sequence and evolutionary analysis of a gorilla foamy virus. J Gen Virol (2010) 0.77
Knockdown of mouse VCAM-1 by vector-based siRNA. Transpl Immunol (2006) 0.77
Obituary: Axel Rethwilm (1959-2014). Retrovirology (2014) 0.77
Chlamydia trachomatis Incidence Using Self-Reports and Serology by Gender, Age Period, and Sexual Behavior in a Birth Cohort. Sex Transm Dis (2017) 0.75